These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 25499836)

  • 1. Beyond the early stages: insights from the ASSURE registry on bioresorbable vascular scaffolds.
    Wöhrle J; Naber C; Schmitz T; Schwencke C; Frey N; Butter C; Brachmann J; Ingwersen M; Drabik A; Markovic S; Mathey DG
    EuroIntervention; 2015 Jun; 11(2):149-56. PubMed ID: 25499836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry.
    Capodanno D; Gori T; Nef H; Latib A; Mehilli J; Lesiak M; Caramanno G; Naber C; Di Mario C; Colombo A; Capranzano P; Wiebe J; Araszkiewicz A; Geraci S; Pyxaras S; Mattesini A; Naganuma T; Münzel T; Tamburino C
    EuroIntervention; 2015 Feb; 10(10):1144-53. PubMed ID: 25042421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry.
    Kraak RP; Hassell ME; Grundeken MJ; Koch KT; Henriques JP; Piek JJ; Baan J; Vis MM; Arkenbout EK; Tijssen JG; de Winter RJ; Wykrzykowska JJ
    EuroIntervention; 2015 Feb; 10(10):1160-8. PubMed ID: 25136885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mid- to long-term outcome of patients treated with everolimus-eluting bioresorbable vascular scaffolds: Data of the BVS registry Göttingen predominantly from ACS patients.
    Hellenkamp K; Becker A; Gabriel YD; Hasenfuß G; Hünlich M; Jacobshagen C; Schillinger W; Schroeter MR
    Int J Cardiol; 2017 May; 234():58-63. PubMed ID: 28258843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial.
    Diletti R; Farooq V; Girasis C; Bourantas C; Onuma Y; Heo JH; Gogas BD; van Geuns RJ; Regar E; de Bruyne B; Dudek D; Thuesen L; Chevalier B; McClean D; Windecker S; Whitbourn RJ; Smits P; Koolen J; Meredith I; Li X; Miquel-Hebert K; Veldhof S; Garcia-Garcia HM; Ormiston JA; Serruys PW
    Heart; 2013 Jan; 99(2):98-105. PubMed ID: 23118346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.
    Diletti R; Serruys PW; Farooq V; Sudhir K; Dorange C; Miquel-Hebert K; Veldhof S; Rapoza R; Onuma Y; Garcia-Garcia HM; Chevalier B
    Am Heart J; 2012 Nov; 164(5):654-63. PubMed ID: 23137495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Safety of Everolimus-Eluting Bioresorbable Vascular Scaffold (BVS) Implantation in Patients With Chronic Total Coronary Occlusions: Acute Procedural and Short-Term Clinical Results.
    Goktekin O; Yamac AH; Latib A; Tastan A; Panoulas VF; Sato K; Erdogan E; Uyarel H; Shah I; Colombo A
    J Invasive Cardiol; 2015 Oct; 27(10):461-6. PubMed ID: 26429848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel approach to treat in-stent restenosis: 6- and 12-month results using the everolimus-eluting bioresorbable vascular scaffold.
    Jamshidi P; Nyffenegger T; Sabti Z; Buset E; Toggweiler S; Kobza R; Cuculi F
    EuroIntervention; 2016 Apr; 11(13):1479-86. PubMed ID: 27107313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population.
    Costopoulos C; Latib A; Naganuma T; Miyazaki T; Sato K; Figini F; Sticchi A; Carlino M; Chieffo A; Montorfano M; Colombo A
    Catheter Cardiovasc Interv; 2015 Jan; 85(1):E10-5. PubMed ID: 24909303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry.
    Gori T; Wiebe J; Capodanno D; Latib A; Lesiak M; Pyxaras SA; Mehilli J; Caramanno G; Di Mario C; Brugaletta S; Weber J; Capranzano P; Sabate M; Mattesini A; Geraci S; Naber CK; Araszkiewicz A; Colombo A; Tamburino C; Nef H; Münzel T
    EuroIntervention; 2016 Aug; 12(5):e550-6. PubMed ID: 26348681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and multimodality imaging results at 6 months of a bioresorbable sirolimus-eluting scaffold for patients with single de novo coronary artery lesions: the NeoVas first-in-man trial.
    Zhang YJ; Wang XZ; Fu G; Jing QM; Wang G; Jin CY; Xie LH; Cai JZ; Xu B; Han YL
    EuroIntervention; 2016 Nov; 12(10):1279-1287. PubMed ID: 27866137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus-eluting Bioresorbable Vascular Scaffold Implantation in Real World and Complex Coronary Disease: Procedural and 30-day Outcomes at Two Australian Centres.
    Robaei D; Back LM; Ooi SY; Pitney MR; Jepson N
    Heart Lung Circ; 2015 Sep; 24(9):854-9. PubMed ID: 25778622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of bioresorbable vascular scaffold Absorb BVS® in patients with stable coronary artery disease: one-year results with special focus on the hybrid bioresorbable vascular scaffolds and drug eluting stents treatment.
    Gil RJ; Bil J; Pawłowski T; Yuldashev N; Kołakowski L; Jańczak J; Jabłoński W; Paliński P
    Kardiol Pol; 2016; 74(7):627-33. PubMed ID: 26779846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus-eluting bioresorbable vascular scaffolds for treatment of complex chronic total occlusions.
    Fam JM; Ojeda S; Garbo R; Latib A; La Manna A; Vaquerizo B; Boukhris M; Vlachojannis GJ; van Geuns RJ; Ezhumalai B; Kawamoto H; van der Sijde J; Felix C; Pan M; Serdoz R; Boccuzzi GG; De Paolis M; Sardella G; Mancone M; Tamburino C; Smits PC; Di Mario C; Seth A; Serra A; Colombo A; Serruys P; Galassi AR; Zijlstra F; Van Mieghem NM; Diletti R
    EuroIntervention; 2017 Jun; 13(3):355-363. PubMed ID: 28218604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of stent size on angiographic and clinical outcomes after implantation of everolimus-eluting bioresorbable scaffolds in daily practice: insights from the ISAR-ABSORB registry.
    Wiebe J; Hoppmann P; Kufner S; Harada Y; Colleran R; Michel J; Giacoppo D; Schneider S; Cassese S; Ibrahim T; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA
    EuroIntervention; 2016 Jun; 12(2):e137-43. PubMed ID: 27180303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twelve-Month Outcomes With a Bioresorbable Everolimus-Eluting Scaffold: Results of the ESHC-BVS Registry at Two Australian Centers.
    Robaei D; Back L; Ooi SY; Pitney M; Jepson N
    J Invasive Cardiol; 2016 Aug; 28(8):316-22. PubMed ID: 26567454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Comparison With Short-Term Follow-Up of Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Stent in Primary Percutaneous Coronary Interventions.
    Cortese B; Ielasi A; Romagnoli E; Varricchio A; Cuculo A; Loi B; Pisano F; Corrado D; Sesana M; La Vecchia L; Summaria F; Tespili M; Silva Orrego P; Tognoni G; Steffenino G
    Am J Cardiol; 2015 Sep; 116(5):705-10. PubMed ID: 26100584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a fully bioresorbable vascular scaffold in patients with coronary artery disease: design of and rationale for the ABSORB III randomized trial.
    Kereiakes DJ; Ellis SG; Popma JJ; Fitzgerald PJ; Samady H; Jones-McMeans J; Zhang Z; Cheong WF; Su X; Ben-Yehuda O; Stone GW
    Am Heart J; 2015 Oct; 170(4):641-651.e3. PubMed ID: 26386787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 6-month clinical outcomes following implantation of the bioresorbable everolimus-eluting vascular scaffold in vessels smaller or larger than 2.5 mm.
    Diletti R; Onuma Y; Farooq V; Gomez-Lara J; Brugaletta S; van Geuns RJ; Regar E; de Bruyne B; Dudek D; Thuesen L; Chevalier B; McClean D; Windecker S; Whitbourn R; Smits P; Koolen J; Meredith I; Li D; Veldhof S; Rapoza R; Garcia-Garcia HM; Ormiston JA; Serruys PW
    J Am Coll Cardiol; 2011 Jul; 58(3):258-64. PubMed ID: 21737016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.